0000000000287607

AUTHOR

Christoph Medler

showing 3 related works from this author

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

2015

In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with r/r follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1-3 prior therapies received Bendamustine (90 mg/m(2), day 1+2) and Rituximab (375 mg/m(2), day 1) with Temsirolimus in doses from 25 to 75 mg added on day 1, 8, 15 of a 28-day cycle. Fifteen (11 MCL, 4 FL) patients were included in the phase I. Median age was 73 years and median pretreatment number was 2. No formal dose-limiting toxicity was observed. Dominant non-hematological side effects were fatigue in 11 (73%), nausea in 9 (60%), mucositis in 7 (47%) and vomiting in 6 patients (40%). Coug…

MaleBendamustineCancer Researchmedicine.medical_specialtyMaximum Tolerated DoseFollicular lymphomaLymphoma Mantle-CellNeutropeniaGastroenterologyAntibodies Monoclonal Murine-Derivedhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisBendamustine HydrochlorideHumansProspective StudiesLymphoma FollicularAgedNeoplasm StagingSirolimusLeukopeniabusiness.industryRemission InductionHematologyMiddle AgedPrognosismedicine.diseaseTemsirolimusSurgerySurvival RateOncologyNitrogen Mustard CompoundsFeasibility StudiesFemaleMantle cell lymphomaRituximabNeoplasm Recurrence LocalSafetymedicine.symptomRituximabbusinessFollow-Up Studiesmedicine.drugLeukemia
researchProduct

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/I…

2016

Abstract Background: mTOR inhibition has been shown to be effective in various subtypes of malignant lymphomas (Smith et al, JCO 2010). Furthermore, in relapsed MCL a phase III trial demonstrated superiority of Temsirolimus to chemotherapy. Although novel treatment options as Ibrutinib have changed the treatment landscape for MCL, no curative potential could be shown for this approach and novel concepts continue to be needed. Several trials provided promising results when Temsirolimus is combined with agents like Rituximab (Ansell et al, Lancet Oncology 2011) or chemoimmunotherapy, as shown in part I (phase I) of the reported trial (Hess, Leukemia, 2015). We now report the final analysis of…

BendamustineOncologymedicine.medical_specialtyImmunologyFollicular lymphoma02 engineering and technologyBiochemistry03 medical and health sciences020210 optoelectronics & photonics0302 clinical medicineMedian follow-upChemoimmunotherapyInternal medicine0202 electrical engineering electronic engineering information engineeringMedicinebusiness.industryCell BiologyHematologymedicine.diseaseChemotherapy regimenTemsirolimusRegimen030220 oncology & carcinogenesisRituximabbusinessmedicine.drugBlood
researchProduct

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Folli…

2020

Abstract. In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous therapies received Bendamustine (90 mg/m2, day 1 + 2) and Rituximab (375 mg/m2, day 1) with Temsirolimus in doses from 25 to 75 mg in phase I and 50 mg Temsirolimus in phase II, added on day 1, 8, 15 of a 28 days cycle. The primary endpoint of the phase II was ORR at the end of treatment. Overall, 39 (29 MCL, 10 FL) patients were included. Median age was 71 years and median pretreatment number was 2. Grade 3/4 non-hematologic adverse events wer…

Bendamustinemedicine.medical_specialtyCancer ResearchLeukopeniabusiness.industrylcsh:RC633-647.5Follicular lymphomaHematologylcsh:Diseases of the blood and blood-forming organsNeutropeniamedicine.diseaseGastroenterology002TemsirolimusArticleRegimenInternal medicinehemic and lymphatic diseasesmedicineMantle cell lymphomaRituximabmedicine.symptombusinessmedicine.drugHemaSphere
researchProduct